Literature DB >> 7160041

Distribution of 13N in rat tissues following intravenous administration of nitroso-labeled BCNU.

B R Freed, R L McQuinn, R S Tilbury, G A Digenis.   

Abstract

The concentrations of label in 16 major organs and tissues of pentobarbital-sedated normal male rats were measured at six time points ranging from 0.2 to 50 min after IV injection of the antitumor drug BCNU labeled in the nitroso position with cyclotron-produced nitrogen-13. Initial (12-s) concentrations in the lungs, kidneys, and heart were 41, 13, and 11 times the whole-body average, respectively. Time for clearance of the first 50% of the injected dose from the circulation was of the order of several seconds. Estimated first-pass extractions of 70% or more were noted in the heart, kidneys, brain, stomach, small intestine, muscle, fat, and bone. Washout of label from the heart and lungs was quite rapid, removing most of the initially extracted 13N from these organs by 2 min after injection. Label concentrations in the kidneys exceeded those in all other tissues studied between 2 and 50 min. Secondary accumulations of 13N were observed in muscle, skin, liver, small intestine, and fat. Label concentrations in a number of tissues closely paralleled the steadily decreasing concentration in blood for various intervals between 5 and 50 min. The results suggest that the toxic insult to lung tissue from IV administered BCNU is effected in a period of several minutes. They also suggest that intra-arterial administration of the drug would significantly raise the target/non-target dose ratio and lower the incidence of pulmonary toxicity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7160041     DOI: 10.1007/bf00257230

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Plasma volume, cell volume, total blood volume and F cells factor in the normal and splenectomized Sherman rat.

Authors:  L Wang
Journal:  Am J Physiol       Date:  1959-01

2.  Severe generalized glutathione reductase deficiency after antitumor chemotherapy with BCNU" [1,3-bis(chloroethyl)-1-nitrosourea].

Authors:  H Frischer; T Ahmad
Journal:  J Lab Clin Med       Date:  1977-05

3.  BCNU and X-ray therapy of intracerebral 9L rat tumors.

Authors:  M Barker; D F Deen; D G Baker
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-09       Impact factor: 7.038

4.  Differential plus polarographic determination of submicrogram quantities of carmustine and related compounds in biological samples.

Authors:  I Bartosek; S Daniel; S Sýkora
Journal:  J Pharm Sci       Date:  1978-08       Impact factor: 3.534

5.  The nitrosoureas and pulmonary toxicity.

Authors:  R B Weiss; D S Poster; J S Penta
Journal:  Cancer Treat Rev       Date:  1981-06       Impact factor: 12.111

6.  Distribution of Bratton-Marshall-positive material in mice following intravenous injections of nitrosoureas.

Authors:  P Kari; W R McConnell; J M Finkel; D L Hill
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  Microsomal metabolism of nitrosoureas.

Authors:  D L Hill; M C Kirk; R F Struck
Journal:  Cancer Res       Date:  1975-02       Impact factor: 12.701

8.  Relationship of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) pharmacokinetics of uptake, distribution, and tissue/plasma partitioning in rat organs and intracerebral tumors.

Authors:  V A Levin; P A Kabra; M A Freeman-Dove
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

9.  The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU.

Authors:  V A Levin; J Stearns; A Byrd; A Finn; R J Weinkam
Journal:  J Pharmacol Exp Ther       Date:  1979-01       Impact factor: 4.030

10.  Phase II study--intra-arterial BCNU therapy for metastatic brain tumors.

Authors:  S Madajewicz; C R West; H C Park; J Ghoorah; A M Avellanosa; H Takita; C Karakousis; R Vincent; J Caracandas; E Jennings
Journal:  Cancer       Date:  1981-02-15       Impact factor: 6.860

View more
  1 in total

1.  Pharmacokinetics of 11C-BCNU in experimental brain tumor.

Authors:  K Sako; M Diksic; S Farrokhzad; Y L Yamamoto; W Feindel
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.